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Abstract 
Background: Endothelial protein C receptor (EPCR) was recently identified as a key receptor for Plasmodium falcipa-
rum erythrocyte membrane protein 1 mediating sequestration of P. falciparum-infected erythrocytes in patients suffer-
ing from severe malaria. Soluble EPCR (sEPCR) inhibits binding of P. falciparum to EPCR in vitro and increased levels of 
sEPCR have been associated with the H3 haplotype of the EPCR encoding PROCR gene. It has been hypothesized that 
elevated sEPCR levels, possibly linked to the PROCR H3 genetic variant, may confer protection against severe forms of 
malaria. This study determined the frequencies of PROCR haplotypes H1–4 and plasma levels of sEPCR in a Tanzanian 
study population to investigate a possible association with severe malaria.
Methods: Study participants were children under 5 years of age admitted at the Korogwe District Hospital (N = 143), 
and diagnosed as having severe malaria (N = 52; including cerebral malaria N = 17), uncomplicated malaria (N = 24), 
or an infection other than malaria (N = 67). In addition, blood samples from 71 children living in nearby villages were 
included. The SNPs defining the haplotypes of PROCR gene were determined by post-PCR ligation detection reaction-
fluorescent microsphere assay.
Results: Individuals carrying at least one H3 allele had significantly higher levels of sEPCR than individuals with no H3 
alleles (P < 0.001). No difference in the frequency of H3 was found between the non-malaria patients, malaria patients 
or the village population (P > 0.1). Plasma levels of sEPCR differed between these three groups, with higher sEPCR 
levels in the village population compared to the hospitalized patients (P < 0.001) and higher levels in malaria patients 
compared to non-malaria patients (P = 0.001). However, no differences were found in the distribution of H3 (P = 0.2) 
or levels of sEPCR (P = 0.8) between patients diagnosed with severe and uncomplicated malaria.
Conclusion: Frequencies of SNPs determining PROCR haplotypes were in concordance with other African studies. 
The PROCR H3 allele was associated with higher levels of sEPCR, confirming earlier findings, however, in this Tanzanian 
population; neither PROCR haplotype nor level of sEPCR was associated with severe malaria, however, larger studies 
are needed to confirm these findings.
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Background
In 2012, there was an estimated 165 million cases of 
malaria in Africa, leading to over half a million deaths 
[1]. Severe and fatal cases of malaria are caused by Plas-
modium falciparum infection [2], and this is precipitated 
by the ability of this parasite to attach infected erythro-
cytes to the microvasculature. This sequestration of para-
sites causes blood occultation and inflammation in host 
organs, including the brain. The mechanisms resulting in 
the development of severe malaria have not yet been fully 
understood, however; recently, the endothelial protein C 
receptor (EPCR) has been identified as a specific recep-
tor for the P. falciparum erythrocyte membrane protein 
1 (PfEMP1) variants mediating sequestration of infected 
erythrocytes in the most severe forms of malaria, includ-
ing severe anaemia and cerebral malaria [3, 4].
EPCR, also known as activated protein C (APC) 
receptor plays a key role in the regulation of coagula-
tion, inflammation and endothelial cell integrity [5–9]. 
It is a transmembrane glycoprotein, mainly expressed 
on endothelial cells, but also on a variety of other cells, 
including neutrophils [10–14]. On endothelial cells, 
EPCR facilitates conversion of circulating plasma zymo-
gen protein C to APC. APC inactivates clotting factors 
and generates anti-inflammatory and broad cytoprotec-
tive effects through protease-activated receptor 1 (PAR-
1) signalling [6, 9, 15]. The PfEMP1 and APC binding 
sites on EPCR overlap and PfEMP1 exhibits a much 
stronger binding to EPCR than APC. Therefore it is likely 
that EPCR-mediated parasite sequestration aggravates 
malaria pathogenesis by disrupting the anti-coagulative, 
anti-inflammatory and cytoprotective effects of APC [3, 
4].
EPCR is also found as a soluble form in the plasma 
(sEPCR) where it binds APC in competition with cellu-
lar bound EPCR [16, 17]. Elevated levels of sEPCR have 
been associated with single nucleotide polymorphism 
(SNPs) variations in the human PROCR gene, encoding 
EPCR. PROCR variants have been studied mostly in asso-
ciation with venous thrombosis [18–21]. Four haplotypes 
are defined by the SNPs: H1–H4 [18–20]. The H3 hap-
lotype has been associated with increased plasma sEPCR 
levels [19, 22, 23] and has been suggested to be a risk fac-
tor for venous thrombosis [19, 21], although other studies 
could not confirm this [18, 20]. Contrary to H3, the H1 
haplotype has been associated with elevated APC plasma 
concentration and a protective effect against venous 
thrombosis [20, 24]. The H4 haplotype has been associ-
ated with a slightly increased risk of venous thrombo-
sis, whereas H2 haplotype has not been associated with 
increased or decreased risks [18].
Studies investigating the association between PROCR 
haplotype, sEPCR plasma levels and susceptibility to 
malaria [25–28] have somewhat conflicting conclusions. 
The A(6936)G SNP-defining H3 was associated with pro-
tection from severe malaria in a Thai population [27], 
whereas no association could be detected between any 
SNPs in the PROCR gene and susceptibility to severe 
malaria in a Ghanaian study [26]. In a study performed 
on malaria patients from Benin, higher sEPCR plasma 
levels were found in patients with cerebral malaria com-
pared to patients with other forms of severe malaria or 
with uncomplicated malaria, whereas cerebral malaria 
was associated with lower sEPCR plasma levels in 
Malawian children [28]. This study set out to determine 
the frequencies of four EPCR haplotypes and sEPCR lev-
els in an East African Tanzanian study population to elu-
cidate possible associations with severe malaria.
Methods
Study population
Study participants were enrolled at the Korogwe Dis-
trict Hospital and from two villages, Kwamasimba and 
Mkokola, in northeastern Tanzania. From Korogwe Dis-
trict Hospital, children under the age of 5  years were 
enrolled, if presenting with any symptoms of malaria, 
after obtaining informed consent from a parent or legal 
guardian. For diagnostics and research, blood samples 
were collected and treatment was initiated if the patients 
were positive by a malaria rapid diagnostic test (mRDT), 
following national guidelines. Children were considered 
as having severe malaria if haemoglobin levels were <5 g/
dl (severe anaemia), assessed with a Blantyre coma score 
below 3 (cerebral malaria), showing clinical signs of res-
piratory distress, or reaching a parasitaemia level above 
200.000 asexual stages/µl (hyperparasitaemia). Children 
not fulfilling the above criteria were defined as having 
uncomplicated malaria, as previously described [29]. 
Furthermore, convalescent blood samples from a sub-set 
of malaria patients were collected after recovery. These 
samples were randomly selected from a database of the 
original study of which all the hospitalized patients of 
this study were part [30, 31].
As part of an ongoing, annual, malariometric, cross-
sectional study in the study communities, blood samples 
were collected from volunteers residing in the villages 
of Mkokola and Kwamasimba, Korogwe district, north-
eastern Tanzania in 2007 who tested negative for P. fal-
ciparum by blood smear microscopy. The study area has 
previously been described by others [32, 33].
Determination of the EPCR haplotypes H1, H2, H3, and H4 
of the PROCR gene
After collection of whole blood, the plasma and buffy coat 
were each separated from the erythrocytes and stored at 
−80 and −20  °C, respectively. DNA was extracted from 
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the buffy coat with the NucleoSpin Blood Kit (Machery–
Nagel) according to manufacturer’s instructions.
EPCR is encoded by the PROCR gene on chromo-
some 20 and consists of four exons and three introns 
[34, 35]. Primers for the PCRs were designed to amplify 
two regions of the PROCR gene which define the H1, H3 
and H4 haplotypes: the T(4414)C and C(4868)T SNPs 
in intron 1, and the A(6936)GSNP in exon 4. H1, H3 
and H4 were defined based on earlier publications [18, 
19], whereas H2 was defined as being none of the above 
(Table 1) [18, 19]. Size and specificity were tested by aga-
rose gel electrophoreses. For each PCR reaction, 1  µl 
DNA was amplified in a 10 µl reaction consisting of 1.5 µl 
H2O, 2.5  µl 3  µM primermix, and 5.0  µl TEMPase Hot 
Start Master (Ampliqon). The reaction was performed in 
a 96-well PCR plate (Starlab GmbH, Hamburg, Germany) 
in a VWRi Duo Cycler (VWR/Bie & Berntsen, Radnor, 
PA, USA).
Following the PCR reactions, the products were mixed, 
and 2 µl used in the succeeding analysis; a ligase detec-
tion reaction-fluorescent microsphere assay (LDR-FMA). 
The LDR-FMA was developed similar to a previously 
described method [36] to analyse the samples for the 
EPCR haplotypes with minor modifications; 2  µl PCR 
product was used in the following ligase detection reac-
tion (LDR), added to a 13  µl mastermix consisting of 
11.3 µl H2O, 0.15 µl 2 µM LDR primermix, 1.5 µl ligase 
reaction buffer, and 0.05  µl (2 units) Taq DNA ligase 
(both from New England Biolabs, Beverly, MA, USA). 
The reaction was performed in a 96-well PCR plate (Star-
lab GmbH, Hamburg, Germany) in a VWRi Duo Cycler 
(VWR/Bie & Berntsen). The conditions of the following 
microsphere assay were modified on a few parameters; 
12  µl TMAC (3  M tetramethyl-ammonium chloride, 
50 mM Tris–HCl (pH 8.0), 3 mM EDTA (pH 8.0), 0.1 % 
SDS)/1.2  µl Streptavidin-R-phycoerythrin conjugate 
(Sigma Aldrich, St Louis, MO, USA) (10  µg/ml) solu-
tion was added to each well in the second hybridiza-
tion; 75 of each microsphere were analysed. All primers 
were designed based on the GenBank accession number 
AF106202 and are shown in Table  2 along with reac-
tion conditions and tags complementary to Luminex 
MagPlex-TAG™ microspheres (Luminex Corp, Austin, 
TX, USA). Control samples were kindly provided by Dr 
Shirley Uitte de Willige from the Department of Haema-
tology, Erasmus University Medical Centre Rotterdam, 
The Netherlands.
Determination of sEPCR in patient plasma samples
The levels of sEPCR in the patient plasma samples were 
determined by enzyme-linked immunosorbent assay 
(ELISA) (Asserachrom, Stago, France) according to man-
ufacturer’s instructions.
Statistical analysis
Differences in mean age and distribution of gender 
between the groups were analysed with Mann–Whitney 
and Chi square test, respectively. The genotype distribu-
tions for each SNP were analysed for deviations from the 
Hardy–Weinberg Equilibrium with The Court Lab Calcu-
lator [37]. Chi square test was used to analyse differences 
in allele or haplotype frequencies. Differences in sEPCR 
levels were analysed by Mann–Whitney tests. All analy-
ses were done using SigmaPlot 12.3 (SPSS Inc.). P val-
ues < 0.05 were considered statistically significant.
Ethical clearance
Ethical clearance for the study was granted by the Tanza-
nia Medical Research Coordinating Committee and Min-
istry of Health and Social Welfare, Tanzania. Informed 
consent was obtained from parents or legal guardians.
Results
Clinical and demographical characteristics of study 
participants
A retrospective selection of samples was collected 
from children under the age of 5  years, admitted at the 
Korogwe District Hospital. Seventy-six children were 
diagnosed with malaria based on mRDTs and positive 
blood smears, 52 with severe malaria, defined as hyper-
parasitaemia (N  =  12), severe anaemia (N  =  19), cer-
ebral malaria (N  =  17) or respiratory distress (N  =  4). 
Sixty-seven children were admitted with infections other 
than malaria (non-malaria group). Blood samples from 
71 children without malaria based on mRDTs from two 
villages in the district, Kwamasimba and Mkokola, were 
also collected. The demographic characteristics of the 
study population are presented in Table 3.
Determination of H1–4 PROCR haplotypes
The specificity of the LDR-FMA methodology was con-
firmed with control DNA samples from individuals with 
Table 1 Haplotypes of the PROCR gene encoding endothe-
lial protein C receptor (EPCR)
The four haplotypes are determined by three SNPs. Nucleotides defining the 










H1 T C A
H2 T T A
H3 T T G
H4 C T A
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known genotypes of the SNPs used to determine the four 
haplotypes. The three SNPs were correctly identified in 
the control samples, with positive read-outs easily dis-
tinguished from the background read-outs in negative 
control samples. Results were furthermore confirmed by 
sequencing of DNA from selected patients (N = 24).
The alleles of three SNPs: T(4414)C, T(4868)C and 
A(6936)G), were determined for 213 individuals and the 
overall distributions for the alleles were found to be in 
Hardy–Weinberg equilibrium (4414: Χ2 = 0.34, P = 0.6; 
4868: Χ2 = 0.25, P = 0.6; 6936: Χ2 = 0.32, P = 0.6). From 
the SNP alleles, the four haplotypes were constructed for 
each individual (Table 1).
Analysis of the sEPCR levels and the relation to PROCR 
haplotypes
Plasma sEPCR level were measured for each individ-
ual and analysed for association to the PROCR haplo-
types (Fig. 1). Plasma levels of sEPCR were significantly 
higher in individuals carrying at least one H3 allele 
[median = 219.1 ng/ml (25/75 quartiles = 171.7/281.6)] 
compared to individuals with no H3 allele [median 
132.9 ng/ml (25/75 quartiles = 113.3/170.5)], P < 0.001. 
No differences in plasma sEPCR were found between 
individuals carrying any of the other three haplotypes 
(P = 0.1, 0.2 and 0.8, for H1, H2 and H4, respectively).
Analysis of sEPCR level and association with disease
Analysis of H3 distribution in malaria patients, non-malaria 
patients and village population (Table 4), showed that there 
was no statistical significant difference between frequency 
of the H3 allele in the three groups (malaria vs. non-malaria 
patients: Χ2 =  0.03, P =  0.8; malaria patients vs. villages: 
Χ2  =  2.5, P  =  0.1; and non-malaria patients vs. villages: 
Χ2 = 2.3, P = 0.1). To determine if high sEPCR plasma levels 
Table 2 Primers and conditions for the PROCR polymerase chain reaction (PCR) and ligase detection reactions (LDR)
Primer sequences and conditions for the PCR and LDR reactions. For the LDR of T(4414)C and C(4868)T the primers were based on the reverse sequence. Each LDR 
consists of three primers per SNP: two allele specific primers with anti-TAGs (small letters) matching the TAG sequence on the microsphere (Luminex xTAG microsphere 
number shown here) and one common primer marked with phosphate (PHOS) at the 5′ end and biotin (BIO) at the 3′ end. The sites of the SNPs are in bold and 
underscored








95 °C 15 min
30 cycles:
95 °C 30 s
60 °C 30 s
72 °C 60 s




251 bp Rv 5′-TGGTGTTTCAGTTGGGGAGT-3′
LDR primers
4414 common 5′-PHOS-TGAGATCATGTCCTTTTCCTACTT-BIO-3′ 95 °C 1 min
40 cycles:
95 °C 15 s
56 °C 2 min
4414 T(A) 5′-ctttctcatactttcaactaatttCTCCACCTGACCCAGGGA-3′ 20
4414 C (G) 5′-ctttcttaatacattacaacatacCTCCACCTGACCCAGGGG-3′ 25
4868 common 5′-PHOS-CTTCAGCCTGGGCCG-BIO-3′
4868 C (G) 5′-catcttcatatcaattctcttattCTGCGGGCAGAGTCAG-3′ 35
4868 T (A) 5′-tactacttctataactcacttaaaCTGCGGGCAGAGTCAA-3′ 29
6936 common 5′-PHOS-GTTTCATCATTGCTGGTGTG-BIO-3′
6936 A 5′-tacttaaacatacaaacttactcaCGTCCTGGTGGGCA-3′ 65
6936 G 5′-atctcaattacaataacacacaaaCGTCCTGGTGGGCG-3′ 67









 Mean ± SD 2.5 ± 1.2 1.7 ± 1.2 3.8 ± 2.7
 Min/max 0.2/5.2 0.1/5.0 1.0/16.2
Gender (n)
 Male 54.7 % (41) 71.2 % (47) 53.1 % (43)
 Female 45.3 % (35) 28.8 % (20) 46.3 % (38)
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was associated with malaria, sEPCR levels were compared 
between the three study groups (Table 5). Malaria patients 
had higher sEPCR levels [median 161.1 ng/ml, (25/75 quar-
tiles = 124.4/213.4)] than patients with other infectious dis-
eases [median 130.6 ng/ml, (25/75 quartiles = 109.5/165.5)], 
P  <  0.001. The sEPCR levels in the village population 
were significantly higher [238.0  ng/ml, (25/75 quar-
tiles = 178.0/292.4)] than in the two groups of hospitalized 
patients (P < 0.001 for both comparisons). In all groups, a 
significantly higher level of sEPCR was seen in individuals 
with at least one H3 allele than in those without (P = 0.009, 
<0.001 and 0.007, for malaria patients, non-malaria patients 
and village population, respectively) (Table 5).
The PROCR haplotypes and sEPCR levels of malaria 
patients were also analysed by comparing patients with 
severe or uncomplicated malaria (Table 6). No difference 
in frequency of the H3 haplotype was detected (Χ2 = 1.9, 
P  =  0.2) or in sEPCR levels (P  =  0.8). The cerebral 
malaria patients (N = 17) were then separated from the 
other severe cases (hyperparasitaemia, severe anaemia 
and respiratory distress) to determine if these patients 
differed in sEPCR level. No difference was found between 
the two groups (P = 0.7).
Finally, to investigate if there was any difference in 
sEPCR level during malaria and 3 weeks post-treatment, 
a sub-set of 28 children was included in a follow-up study 
(Fig. 2). The level of sEPCR was significantly higher dur-
ing convalescence [median 163.8  ng/ml, (25/75 quar-
tiles = 126.7/280.1)], than during acute infection [median 
138.3 ng/ml, (25/75 quartiles = 116.6/164.3)], P = 0.001.
Discussion
This study investigated the four defined EPCR haplo-
types resulting from SNPs of the PROCR gene and their 
possible association with the level of sEPCR and disease 
outcome in Tanzanian patients infected with falcipa-
rum malaria. Based on earlier findings, it was hypoth-














































































P < 0.001 
P = 0.1 P = 0.2 
P = 0.8 
Fig. 1 Soluble endothelial protein C receptor (sEPCR) levels of the total study population in the four haplotypes. Hx are defined as all haplotypes 
but the one given for each of the four analyses. A statistically significant difference was found with higher levels of sEPCR in carriers of at least one 
H3 allele compared to carriers of none. The significance level was set to P < 0.05
Table 4 Distribution of the four haplotypes in hospitalized 
patients and village population
The four haplotypes were determined in all three study groups. No significant 
differences were found in the distribution of the haplotypes. The significance 









H1 15.8 % (24) 14.2 % (19) 14.8 % (21)
H2 66.5 % (101) 68.7 % (92) 65.5 % (93)
H3 10.5 % (16) 10.5 % (14) 4.9 % (7)
H4 7.2 % (11) 6.7 % (9) 14.8 % (21)
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of sEPCR, could confer a protective advantage against 
severe malaria.
The haplotype distribution in this Tanzanian popula-
tion differed from a Caucasian population [18], with a 
higher frequency of H2 (66.6 vs. 42.9  %) and lower fre-
quency of H1 (15.0 vs. 39.4  %) while the frequency of 
Table 5 Soluble endothelial protein C receptor (sEPCR) levels of hospitalized patients and village population
sEPCR levels were determined in all patients and village samples. Individuals who carry at least one H3 allele had higher levels of sEPCR than those carrying none. 
This was found in all three groups. Statistically significant differences were found in the general sEPCR level between all three groups. The non-malaria patient group 
differed from both the malaria and village groups by having lower levels of sEPCR (P = 0.001 and P < 0.001, respectively), and the malaria patient group differed from 
































































































Table 6 Haplotype distribution and  soluble endothelial 
protein C receptor (sEPCR) levels in severe and uncompli-
cated malaria patients
The haplotype distribution and sEPCR levels are shown for the severe and 
uncomplicated malaria patients. A difference in sEPCR level was seen in 
individuals with at least one H3 allele compared to those with none, however, 
this was only seen in patients with severe and not uncomplicated malaria. No 
differences were found in the haplotype distributions or in the general sEPCR 



























H1 (n) 16.4 % (17) 14.6 % (7)














H2 (n) 66.4 % (69) 66.7 % (32)














H3 (n) 7.7 % (8) 16.7 % (8)














H4 (n) 9.6 % (10) 2.1 % (1)
Fig. 2 Soluble endothelial protein C receptor (sEPCR) levels in acute 
malaria patients and after follow-up. sEPCR levels were measured 
in acute ill malaria patients and after recovery (N = 28). The level 
of sEPCR was significantly lower (P = 0.001) during acute illness 
compared to the same patients after recovery. The significance level 
was set to P < 0.05
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H3 did not differ significantly between the two popula-
tions (8.6 vs. 12.7 %) [18]. SNPs of the PROCR gene have 
also been studied without defining these haplotypes in 
Ghana, Benin and Thailand [25–27]. In Ghana and Benin, 
very similar frequencies of the SNPs defining H1 (4868)C 
and H3 (6936G) were found compared to this Tanzanian 
study. In Ghana, the (4868)C was found at a frequency of 
12.6 % compared to 16.3 % in this study. The (6936)G was 
found at frequencies of 5.9 % (Ghana) and 8.0 % (Benin) 
compared to the 9.9 % in Tanzania [25, 26]. Lastly, a Thai 
study [27] found a frequency of 30.5  % of the (6936)G, 
which is significantly higher than was found in Tanzania, 
Ghana and Benin [27].
In this study, the haplotypes were studied in three 
groups: malaria patients, patients with other infections 
and a village population. Malaria patients were divided 
into sub-groups based on severity of the disease and dis-
ease manifestation. No differences in H3 frequency were 
found between any of the groups. This indicates that the 
studied PROCR haplotypes are not a determining factor 
for severity of the disease, which is in concordance with 
findings from the study in Ghana, investigating over 40 
SNPs, where none of the investigated SNPs was associ-
ated with severe malaria [26]. Both the present study and 
the Ghanaian study contradicts findings from the Thai 
study, where the (6936)G allele was associated with pro-
tection against severe malaria. However, this association 
was found when using a recessive inheritance model and 
not adjusting for multiple testing [27]. Applying a reces-
sive inheritance model to the data of the study in Ghana 
found no association between (6936)G and protection 
either [26]. The study participants in the Thai study were 
significantly older than in this current study, and the con-
tradictory findings may be biased if age has an effect on 
sEPCR level. Differences in selection pressure may also 
contribute to the differences found between populations.
The present study also examined the association 
between sEPCR plasma level and malaria symptoms. 
Non-malaria patients were found to have the lowest 
levels of sEPCR, whereas the village population had the 
highest, and no difference was seen between uncom-
plicated, severe or cerebral malaria patients. Increased 
sEPCR levels were found in individuals who had recov-
ered from a malaria episode. These findings differ from 
the study in Benin, where high levels of sEPCR were 
associated with cerebral malaria and death [25], and 
surviving cerebral malaria patients had reduced sEPCR 
after 30 days to similar levels as seen for other severe and 
uncomplicated malaria patients [25]. One explanation for 
these differences could be that the patient group studied 
in Benin had progressed to a more severe state of malaria, 
perhaps causing acutely increased sEPCR levels, although 
this theory is compromised by the high sEPCR levels in 
the Tanzanian village population and that the Tanza-
nian patients recovering from malaria had an increase in 
sEPCR levels. Both these current findings and the find-
ings from Benin are inconsistent with observations done 
in Malawi, where cellular-bound EPCR appeared to be 
reduced on endothelial cells with sequestered parasites, 
and sEPCR levels were lower in plasma but higher in cer-
ebrospinal fluid in cerebral malaria patients compared to 
non-malaria febrile controls [28].
These discrepancies may be related to different dis-
ease state and ethnicity of patients, as well as the oppos-
ing effects that sEPCR binding to maturing circulating 
parasites [3], sEPCR shedding from endothelial cells, and 
immune acquisition may have on sEPCR plasma levels 
during disease.
As observed in previous studies [19, 22, 23, 25] this 
study showed that higher levels of sEPCR were associ-
ated with individuals with at least one H3 allele. Inter-
estingly, a high plasma level of sEPCR was also seen in 
a sub-set of study participants with no H3 allele. In the 
Ghanaian study, the PROCR gene was sequenced and 
thoroughly examined to identify new SNPs [26]. How-
ever, sEPCR levels were not determined, and it is possible 
that some of these, or unidentified SNPs, are associated 
with elevated sEPCR plasma levels and protection against 
malaria; indeed, as suggested, any protective role of 
sEPCR may not be simply reflected by a haplotype-dis-
ease relationship.
PfEMP1 binds EPCR with high specificity and affinity, 
and with a 3D structure preserved across sequence diver-
sity [4]. This interaction inhibits natural APC binding 
and is likely to aggravate pathogenesis of severe malaria. 
As PfEMP1 precludes APC binding by interaction at the 
same binding pocket site on EPCR as APC, it is unlikely 
that the EPCR could mutate to evade PfEMP1 binding 
without the detrimental loss of APC function. If protec-
tive mechanisms have developed in face of the PfEMP1–
EPCR interaction, these could relate to the sEPCR level, 
e.g., through epigenetic control of PROCR expression. 
Thus, a good starting point would be larger studies of 
sEPCR levels in malaria-exposed populations to examine 
if elevated sEPCR levels do serve as a mechanism of pro-
tection against malaria.
Conclusion
The four defined haplotypes of the PROCR gene were stud-
ied in relation to malaria and sEPCR level in a Tanzanian 
study population and hospitalized patients. Frequencies of 
SNPs determining PROCR haplotypes were in concordance 
with other African studies. PROCR H3 was associated with 
higher levels of sEPCR, confirming earlier findings, how-
ever, in this Tanzanian population; neither PROCR haplo-
type nor level of sEPCR was associated with severe malaria.
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